A Phase I/II Trial of Herceptin and ZD1839 (Iressa, NSC #715055, IND#61187) in Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu (erbB-2)
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2015
At a glance
- Drugs Gefitinib (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 23 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Sep 2005 New trial record.